April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Efficacy of Adalimumab in Adult and Pediatric Refractory Uveitis: A Multicenter Study
Author Affiliations & Notes
  • D. Salom
    Ophthalmology, La Fe University Hospital, Valencia, Spain
  • M. Diaz-Llopis
    Ophthalmology, La Fe University Hospital, Valencia, Spain
  • G. Ortega
    Laboratory of Ocular Immunology and Uveitis., Instituto Nacional de Rehabilitacion., Calz. Mexico-Xochimilco, Mexico
  • M. Cordero
    Ophthalmology, Hospital de León, León, Spain
  • M. Suarez-de-Figueroa
    Ophthalmology, Hospital Ramon y Cajal., Madrid, Spain
  • C. Fernandez-Cid
    Ophthalmology, Hospital de Pontevedra., Pontevedra,, Spain
  • A. Fonollosa
    Ophthalmology, Hospital de Cruces., Bilbao, Spain
  • J. Benitez-del-Castillo
    Ophthalmology, Hospital Clínico San Carlos., Madrid, Spain
  • J. L. Olea
    Ophthalmology, Hospital Son Dureta., Palma de Mallorca, Spain
  • F. Arevalo
    Retina & Vitreous Service, Ophthalmology, Clinica Oftalmologica Centro Caracas., Caracas., Venezuela
  • Footnotes
    Commercial Relationships  D. Salom, None; M. Diaz-Llopis, None; G. Ortega, None; M. Cordero, None; M. Suarez-de-Figueroa, None; C. Fernandez-Cid, None; A. Fonollosa, None; J. Benitez-del-Castillo, None; J.L. Olea, None; F. Arevalo, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5270. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Salom, M. Diaz-Llopis, G. Ortega, M. Cordero, M. Suarez-de-Figueroa, C. Fernandez-Cid, A. Fonollosa, J. Benitez-del-Castillo, J. L. Olea, F. Arevalo; Efficacy of Adalimumab in Adult and Pediatric Refractory Uveitis: A Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5270.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The aim of this study was to assess the efficacy and safety of adalimumab in treating refractory autoimmune uveitis.

Methods: : : This work was a retrospective, noncomparative, nonrandomized, international, multicenter study. Seventy-two patients with refractory uveitis of different etiologies (Juvenile Idiopathic Arthritis, Pars Planitis, Behçet Disease, Vogt Koyanagy Harada syndrome, Ankilosing Spondilitis, Inflammatory Bowel Disease, Sarcoidosis, Lupus, Rheumatoid Arthritis, Birdshot Coriorretinopathy, Sympathetic Ophthalmia, and uveitis of Idiopathic origin) meeting eligibility criteria received a 40-mg subcutaneous (s.c.) injection of adalimumab every other week during 6 months.

Results: : All patients underwent an outcome assessment at month 6. All patients had an active intraocular inflammation at baseline, and 51 patients (70%) achieved control of their inflammation with adalimumab at the end of follow-up. After optic coherence tomography, 20 patients (28%) had cystoid macular edema (CME) at baseline, and at the end of follow-up there was a complete resolution of CME in 14 of these 20 eyes. All patients were able to reduce at least 50% of the dose of the concomitant immunosuppressive drugs at the end of follow-up. Adalimumab was well tolerated in all patients, and only local minor side effects at the s.c. injection site were observed. Nevertheless, 9 patients (12%) had moderate to severe relapses during the follow-up period, and 17 patients (23.6%) had minor relapses during the follow-up that were controlled with 1 periocular steroid injection.

Conclusions: : Adalimumab seems to be an effective, safe therapy for the management of refractory uveitis and may provide the possibility to reduce the concomitant immunosuppressive drugs in these patients. Further long-term studies are warranted to determine the safety and efficacy of adalimumab in treating intraocular inflammation.

Keywords: inflammation • uveitis-clinical/animal model • uvea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.